<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" id="table1" position="float"><object-id pub-id-type="doi">10.7554/eLife.47198.015</object-id><label>Table 1.</label><caption><title>Summary of heterozygous <italic>AMH</italic> or <italic>AMHR2</italic> mutations identified in patients with congenital hypogonadotropic hypogonadism.</title><p>cDNA and protein changes are based on reference cDNA sequence NM_000479.4 (<italic>AMH</italic>) and NM_020547.3 (<italic>AMHR2</italic>). Functional validation of the mutants has been performed in vitro evaluating AMH secretion in COS-7 cells, cell motility in GN11 cells, and measuring GnRH secretion in GT1-7 cells for nCHH-associated mutants. CHH, congenital hypogonadotropic hypogonadism; nCHH, normosmic CHH; KS, Kallmann syndrome; Sex: F: female; M: male; Inheritance: F: familial, S: sporadic; Puberty: A: absent puberty, P: partial puberty. MAF, minor allele frequency; &#8595;, decreased; NS, not significant; NA, not applicable.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Gene</th><th rowspan="2">Family</th><th rowspan="2">Subject</th><th rowspan="2">Diagnosis</th><th rowspan="2">Sex</th><th rowspan="2">Inheritance</th><th rowspan="2">Puberty</th><th rowspan="2">Associated phenotypes</th><th rowspan="2">dbSNP number</th><th rowspan="2">Nucleotide change</th><th rowspan="2">Amino acid change</th><th rowspan="2">MAF (%) gnomAD MaxPop</th><th colspan="3">In vitro studies</th></tr><tr><th>Released AMH (COS-7 cells)</th><th>Cell motility (GN11 cells)</th><th>GnRH secretion (GT1-7 cells)</th></tr></thead><tbody><tr><td rowspan="3"><italic>AMH</italic></td><td>1</td><td>II-1</td><td>nCHH</td><td>M</td><td>F</td><td>P</td><td>High-arched palate Deviated nasal septumHyperlaxity</td><td>rs200226465</td><td>c.295A&#160;&gt;&#160;T</td><td>p.Thr99Ser</td><td>0.044</td><td>&#8595;&#8595;</td><td>&#8595;&#8595;</td><td>&#8595;&#8595;</td></tr><tr><td>&#8195;2</td><td>II-1</td><td>KS</td><td>M</td><td>S</td><td>A</td><td>Cryptochidism</td><td>rs370532523</td><td>c.451C&#160;&gt;&#160;T</td><td>p.Pro151Ser</td><td>0.011</td><td>&#8595;&#8595;</td><td>&#8595;&#8595;</td><td/></tr><tr><td>&#8195;3</td><td>II-2</td><td>KS</td><td>F</td><td>F</td><td>P</td><td>Osteoporosis Scoliosis</td><td>rs752574731</td><td>c.714C&#160;&gt;&#160;A</td><td>p.Asp238Glu</td><td>0.006</td><td>&#8595;&#8595;</td><td>&#8595;&#8595;</td><td/></tr><tr><td><italic>AMHR2</italic></td><td>4</td><td>II-1</td><td>nCHH</td><td>F</td><td>S</td><td>A</td><td>Osteoporosis</td><td>rs764761319</td><td>c.1330_1356del</td><td>p.Gly445_Leu453del</td><td>0.093</td><td/><td>&#8595;&#8595;</td><td>&#8595;&#8595;</td></tr></tbody></table></table-wrap>